ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,860.00
0.49%
S&P ASX All Technology
3,102.60
0.47%
Brent Oil
79.395
0.00%
US Dollar vs AUD
1.51745
0.00%
Bitcoin
69,317.80
-0.02%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Synaptogenix Inc (SNPX)

  7. Synaptogenix Inc (SNPX) News

SNPX

Synaptogenix (SNPX)

Synaptogenix Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNPX
DateTimeSourceHeadlineSymbolCompany
16/05/202407:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
07/05/202423:00PR Newswire (US)Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryNASDAQ:SNPXSynaptogenix Inc
24/04/202423:15PR Newswire (US)Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:SNPXSynaptogenix Inc
09/04/202423:15PR Newswire (US)Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsNASDAQ:SNPXSynaptogenix Inc
03/04/202423:00PR Newswire (US)Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:SNPXSynaptogenix Inc
07/02/202402:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNPXSynaptogenix Inc
22/12/202309:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
20/12/202301:00PR Newswire (US)Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersNASDAQ:SNPXSynaptogenix Inc
07/12/202301:00PR Newswire (US)Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sNASDAQ:SNPXSynaptogenix Inc
15/11/202309:05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNPXSynaptogenix Inc
14/11/202309:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNPXSynaptogenix Inc
07/11/202309:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
04/11/202308:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNPXSynaptogenix Inc
03/11/202300:00PR Newswire (US)Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyNASDAQ:SNPXSynaptogenix Inc
26/09/202323:00PR Newswire (US)Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
23/09/202306:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
07/09/202323:00PR Newswire (US)Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent StudyNASDAQ:SNPXSynaptogenix Inc
15/08/202307:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
19/07/202323:00PR Newswire (US)Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple SclerosisNASDAQ:SNPXSynaptogenix Inc
19/07/202322:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
13/07/202323:00PR Newswire (US)Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of NeuroscienceNASDAQ:SNPXSynaptogenix Inc
23/06/202307:15Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNPXSynaptogenix Inc
16/05/202306:51Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SNPXSynaptogenix Inc
29/04/202307:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNPXSynaptogenix Inc
15/04/202307:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNPXSynaptogenix Inc
01/04/202307:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNPXSynaptogenix Inc
01/04/202307:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNPXSynaptogenix Inc
01/04/202307:22Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNPXSynaptogenix Inc
01/04/202307:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNPXSynaptogenix Inc
22/03/202308:24Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SNPXSynaptogenix Inc
 Showing the most relevant articles for your search:NASDAQ:SNPX

Your Recent History

KUCN
TRYUSDT
Trias Token
BIT
P22JQ4
NLBNPIT22JQ4 20351221 6....
TSX
SID
CI US Trendleaders Index...
TG
B8F
Biofrontera
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved